Fig. 3From: Efficacy and safety of low-dose Sirolimus in LymphangioleiomyomatosisCategorical changes in lung function before and after treatment. Changes in disease progression (any decline in FEV1) before and after treatment in all subjects a, in the low-dose group b and in the conventional-dose group c. Bars show the proportion of patients in each group. Abbreviations: Pre_12M, 12 months before treatment; Post_12M, 12 months after treatment; Post_24M, 24 months after treatment; FEV1, forced expiratory volume in 1 s. *p < 0.05 (compared with 12 months before treatment)Back to article page